Beam Therapeutics Inc. (NASDAQ: BEAM) is a Healthcare company (Biotechnology) with a market capitalization of $2.1B. The Maz Rating grades it against the other companies in its sector.
Beam Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $20.65, Beam Therapeutics Inc. trades at 14.8x sales and 2.3x book value. Over the last twelve months it generated about $144M of revenue and a net loss of $102M. It runs an operating margin of -267.7% and a net margin of -73.0%. It shows return on equity of -9.7%, return on invested capital of -32.6% and a free cash flow yield of -18.5%. On the balance sheet: a debt-to-equity ratio of 0.26 and a current ratio of 13.00. Over the past 52 weeks the share price ranged from $20.23 to $38.26, with a beta of 2.22.
Beam Therapeutics Inc. does not currently pay a dividend.
28 Wall Street analyst ratings cover the stock: 19 Buy, 8 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Beam Therapeutics Inc. (BEAM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.72% / 30% · (Cash+Inv) / Mkt Cap (36m) 38.7% / 30% · Interest income / Revenue 1985.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 3.72% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 38.7% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 1985.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 3.72% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 38.7% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 1985.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 8.10% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 82.8% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 1985.0% / 5% | Fail |
| FTSE | Debt / Total Assets 7.91% / 33.33% · (Cash+ST Inv) / Total Assets 82.3% / 33.33% · (Cash+Recv) / Total Assets 82.3% / 33.33% · Interest income / Revenue 1985.0% / 5% | Fail |
No. As of September 2026, Beam Therapeutics Inc. (BEAM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Beam Therapeutics Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 1985.0% of each dividend: Beam Therapeutics Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.